Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dutch biopharmaceutical firm IQ Corporation has reached a key milestone in the development of anthrax monoclonal antibody treatments, having successfully achieved its clone generation objectives.
Subscribe to our email newsletter
IQ announced that it has successfully completed PER.C6 clone generation for the production of its two fully human monoclonal antibodies, or mAbs, against the anthrax lethal toxin components lethal factor and protective antigen. The clone generation programs were conducted by Invitrogen’s PD-Direct services for IQ under a licensing agreement with IQ’s fellow Netherlands-based companies, Crucell and DSM.
The PD-Direct services provide access to numerous process development capabilities, including vector construction, media and cell line optimization, and scale-up for manufacturing.
“We are very excited about the successful achievement of our clone generation objectives. It enables IQ to advance its unique strategy of the combined application of two different monoclonal antibodies for the treatment of anthrax,” said Dr Herman Groen, chief scientific officer at IQ.